The short answer
Vitamin K1 can reduce warfarin's anticoagulant effect. That interaction is used intentionally by clinicians in some reversal situations, but an unplanned supplement change can move INR out of range. The usual dietary goal is consistency, not eliminating vitamin K or starting a supplement without supervision.
What this answer covers
Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms.
- Supplement or preparation
- Vitamin K1
- Medication ingredient
- warfarin
What does the evidence show?
Warfarin acts on vitamin K-dependent clotting, and the inspected label advises maintaining a consistent dietary intake. A controlled multivitamin study found that adding 25 micrograms of vitamin K1 daily reduced INR particularly in patients selected for low vitamin K1 status. Separately, a randomized trial in over-anticoagulated patients found that clinician-administered oral vitamin K lowered INR faster than placebo. The latter study demonstrates deliberate reversal under supervision, not a routine self-treatment schedule.
Which forms and conditions matter?
Vitamin K1 is an exact chemical form. Vitamin K2 products contain different menaquinones and should not be substituted in this evidence record. The quantity in a multivitamin differs greatly from a medicinal reversal dose. Clinical context also changes the meaning of an INR reduction: it may be intended during over-anticoagulation but undesirable when a person is stable on warfarin.
What should I discuss with my care team?
Keep dietary vitamin K reasonably consistent and discuss starting, stopping or changing a vitamin K-containing supplement with the anticoagulation service. Do not eliminate vegetables or use extra vitamin K to correct a home INR result on your own. Any deliberate supplementation or reversal should be incorporated into the clinician's warfarin and INR plan. Clock-time separation does not remove vitamin K's effect on clotting-factor production.
How certain is the answer?
The interaction is established, but the response to a particular intake change depends on baseline status and the managed regimen. These studies do not mean everyone needs vitamin K tablets. Unplanned changes can undermine anticoagulation; stopping an established vitamin K intake can also change control.
Evidence and practical considerations
Absorption & effectiveness
Vitamin K1 can reduce warfarin's anticoagulant effect. That interaction is used intentionally by clinicians in some reversal situations, but an unplanned supplement change can move INR out of range. The usual dietary goal is consistency, not eliminating vitamin K or starting a supplement without supervision.
- Exact scope
- Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms. with Oral warfarin, including warfarin sodium tablets with the warfarin active moiety.
- Medication form and route
- oral warfarin
- Timing or duration
- Study-specific durations are described in each source exposure; no universally safe exposure duration has been established.
What remains uncertain
- The interaction is established, but the response to a particular intake change depends on baseline status and the managed regimen. The studies do not create a general requirement for vitamin K tablets. The imported broad safety statement should identify the clinically relevant direction: unplanned antagonism can undermine anticoagulation, while stopping an established intake can also change control.
Factors that may matter: Exact supplement preparation and other ingredients; Starting, stopping or changing supplement intake; Baseline anticoagulation control and clinician-supervised monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral warfarin sodium tablets.
The label advises closer INR monitoring when botanicals are started or stopped, identifies variable botanical composition and lists selected potential interactions. Vitamin K intake should remain consistent.
How this applies: Oral warfarin sodium has warfarin as its active moiety. Label-level botanical and vitamin K monitoring advice applies; it is not proof of this exact supplement effect. Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms.
Regulatory precautions do not quantify the incidence for every exact preparation or prove an interaction for an unlisted ingredient. Warfarin sodium is bridged to the warfarin active moiety only for the oral product.
Source 2: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 warfarin-treated adults selected for low vitamin K1 status (nine) or normal status (seven).
Subtherapeutic INR occurred in nine of nine low-status patients and one of seven normal-status patients; median INR fell 0.51 in the low-status group.
How this applies: Direct low-dose vitamin K1-containing multivitamin study. Applies to vitamin K1 and to multivitamins containing it; not evidence that all multivitamins require or produce the same effect. Exact package scope: Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms.
Small selected cohort; formulation contained multiple ingredients and results do not apply to every multivitamin. This is evidence of a formulation-dependent interaction, not a general requirement for supplementation.
Source 3: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 89 warfarin-treated patients with INR 4.5 to 10 who did not need immediate reversal.
Vitamin K more often reduced INR to the trial target by the following day.
How this applies: Direct oral vitamin K1 for supervised reversal of excessive warfarin anticoagulation. This does not support unsupervised supplementation or treating every vitamin K exposure as harmful. Exact package scope: Vitamin K1 (phylloquinone/phytonadione) with oral warfarin. Routine food intake, low-dose supplements and clinician-directed reversal are different use cases. Findings are not automatically transferred to vitamin K2 forms.
Treatment of over-anticoagulation, not routine supplementation or a self-management protocol; no transfer to vitamin K2.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and contradictory findings assessed for this exact pair. Article drafted and existing statements adjudicated. Clinical sign-off has not been recorded. | |
| Consumer explanations clarified without changing the evidence assessment. | |
| Research summary published |
Article revision: 3cb4c1b9469533e7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.